Research Topics
Genomes and Genes
| hiv 1SummarySummary: The type species of LENTIVIRUS and the etiologic agent of AIDS (ACQUIRED IMMUNODEFICIENCY SYNDROME). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Top Publications
Research Grants
| Scientific Experts
|
Detail Information
Publications
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandSupachai Rerks-Ngarm
Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
N Engl J Med 361:2209-20. 2009..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionBrandon F Keele
Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
Proc Natl Acad Sci U S A 105:7552-7. 2008....
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replicationRenate König
Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
Cell 135:49-60. 2008..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionJesus F Salazar-Gonzalez
University of Alabama at Birmingham, Birmingham, AL 35294, USA
J Exp Med 206:1273-89. 2009..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
Tetherin inhibits HIV-1 release by directly tethering virions to cellsDavid Perez-Caballero
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
Cell 139:499-511. 2009....
Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanismJanet L Douglas
Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
J Virol 83:7931-47. 2009..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
Microbial translocation is a cause of systemic immune activation in chronic HIV infectionJason M Brenchley
Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Med 12:1365-71. 2006..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
Antibody neutralization and escape by HIV-1Xiping Wei
Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
Nature 422:307-12. 2003..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
Identification of host proteins required for HIV infection through a functional genomic screenAbraham L Brass
Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
Science 319:921-6. 2008..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
Early antiretroviral therapy and mortality among HIV-infected infantsAvy Violari
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
N Engl J Med 359:2233-44. 2008..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factorChristine Goffinet
Department of Virology, University of Heidelberg, Heidelberg, Germany
Cell Host Microbe 5:285-97. 2009..Thus, HIV-1 Vpu suppresses the expression of the CD317 antiviral factor in human cells, and the species-specific resistance to this suppression may guide the development of small animal models of HIV infection...
The immune response during acute HIV-1 infection: clues for vaccine developmentAndrew J McMichael
Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Nat Rev Immunol 10:11-23. 2010..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infectionEberhard W Fiebig
Department of Laboratory Medicine, University of California, San Francisco, CA, USA
AIDS 17:1871-9. 2003..Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection...
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, ThailandPunnee Pitisuttithum
Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
J Infect Dis 194:1661-71. 2006....
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1A Trkola
Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
J Virol 70:1100-8. 1996..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infectionNilu Goonetilleke
Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
J Exp Med 206:1253-72. 2009..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoproteinAnna Le Tortorec
Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
J Virol 83:11966-78. 2009..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisM Juliana McElrath
Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Lancet 372:1894-905. 2008..We assessed vaccine-induced immunity and its potential contributions to infection risk...
Genome-scale RNAi screen for host factors required for HIV replicationHonglin Zhou
Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
Cell Host Microbe 4:495-504. 2008..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1Richard E Haaland
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
PLoS Pathog 5:e1000274. 2009....
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistanceChunlin Wang
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
Genome Res 17:1195-201. 2007..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencingAstrid D Haase
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4508 Basel, Switzerland
EMBO Rep 6:961-7. 2005..The TRBP-Dicer interaction shown raises interesting questions about the potential interplay between RNAi and interferon-PKR pathways...
HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomesYukie Iwabu
Department of Pathology, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
J Biol Chem 284:35060-72. 2009..Also, we propose the following configuration of BST-2 in tethering virions to the cell surface; each of the dimerized BST-2 molecules acts as a bridge between viral and cell membranes...
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapyPeter W Hunt
Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
J Infect Dis 197:126-33. 2008....
A quantitative assay for HIV DNA integration in vivoS L Butler
Infectious Disease Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA
Nat Med 7:631-4. 2001..The integration assay employs a novel quantitative form of Alu-PCR that should be generally applicable to studies of integrating viruses and gene transfer vectors...
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tractSaurabh Mehandru
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
J Exp Med 200:761-70. 2004..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical...
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal traffickingRichard S Mitchell
Department of Medicine, University of California San Diego, La Jolla, CA, USA
PLoS Pathog 5:e1000450. 2009..Together, the data support a model in which Vpu co-opts the beta-TrCP/SCF E3 ubiquitin ligase complex to induce endosomal trafficking events that remove BST-2 from its site of action as a virion-tethering factor...
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02)Sophie Limou
Conservatoire National des Arts et Metiers, Universite Paris 7, Paris, France
J Infect Dis 199:419-26. 2009..The present study, the first GWAS of HIV-1 nonprogressors, underscores the potential for some HLA genes to control disease progression soon after infection...
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletionEri Miyagi
Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
Proc Natl Acad Sci U S A 106:2868-73. 2009....
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityPatrick Dorr
Discovery Biology, Pfizer Global Research and Development Sandwich Laboratories, Kent CT13 9NJ, United Kingdom
Antimicrob Agents Chemother 49:4721-32. 2005..Clinical trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS...
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivoAthe M N Tsibris
Massachusetts General Hospital, Boston, Massachusetts, United States of America
PLoS ONE 4:e5683. 2009..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
Molecular architecture of native HIV-1 gp120 trimersJun Liu
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Nature 455:109-13. 2008..Our findings elucidate the structure and conformational changes of trimeric HIV-1 gp120 relevant to antibody neutralization and attachment to target cells...
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu proteinNanette Van Damme
The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
Cell Host Microbe 3:245-52. 2008....
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infectionE S Gray
AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
J Virol 81:6187-96. 2007..These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection...
HIV-1 integration in the human genome favors active genes and local hotspotsAstrid R W Schroder
Infectious Disease Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
Cell 110:521-9. 2002..4 kb region containing 1% of sites. These data document unexpectedly strong biases in integration site selection and suggest how selective targeting promotes aggressive HIV replication...
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?Leonidas Stamatatos
1Seattle Biomedical Research Institute, Seattle, Washington, USA
Nat Med 15:866-70. 2009..A concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV-1...
A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replicationMan Lung Yeung
Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892 0460, USA
J Biol Chem 284:19463-73. 2009..We discuss the similarities and differences between our shRNA findings for HIV-1 using a spreading infection assay in human Jurkat T-cells and results from other investigators who used siRNA-based screenings in HeLa or 293T cells...
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variantsM R Abrahams
Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa
J Virol 83:3556-67. 2009....
Decline in the AIDS and death rates in the EuroSIDA study: an observational studyA Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 362:22-9. 2003..Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe...
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 TrialBertran Auvert
Hopital Ambroise Pare, Assitance Publique Hôpitaux de Paris, Boulogne, France
PLoS Med 2:e298. 2005..Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled intervention trial was conducted in a general population of South Africa to test this hypothesis...
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8Florian Heil
Institute of Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, Trogerstr 9, D 81675 Munich, Germany
Science 303:1526-9. 2004..These data suggest that ssRNA represents a physiological ligand for TLR7 and TLR8...
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmissionCynthia A Derdeyn
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
Science 303:2019-22. 2004..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
HIV enters cells via endocytosis and dynamin-dependent fusion with endosomesKosuke Miyauchi
Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Cell 137:433-44. 2009..These findings imply that HIV-1 infects cells via endocytosis and envelope glycoprotein- and dynamin-dependent fusion with intracellular compartments...
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 updateDiane E Bennett
World Health Organization, Geneva, Switzerland
PLoS ONE 4:e4724. 2009..The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions...
Setting the stage: host invasion by HIVFlorian Hladik
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Nat Rev Immunol 8:447-57. 2008..Furthermore, we discuss the gaps in our knowledge that are relevant to future studies, which will shape strategies for effective HIV prevention...
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradationBastien Mangeat
Department of Dermatology and Venereology, University Hospitals and Medical School of Geneva, University of Geneva, Switzerland
PLoS Pathog 5:e1000574. 2009..Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication...
Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4K Saksela
Rockefeller University, New York, NY 10021
EMBO J 14:484-91. 1995..Thus, CD4 down-regulation and promotion of viral growth are two distinct functions of Nef, and the latter is mediated via SH3 binding...
The cell biology of HIV-1 virion genesisPaul D Bieniasz
Howard Hughes Medical Institute, Aaron Diamond AIDS Research Center, New York, NY 10016, USA
Cell Host Microbe 5:550-8. 2009..Here, I review recent progress in these three areas...
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapyXiping Wei
Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
Antimicrob Agents Chemother 46:1896-905. 2002..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan AfricaCatherine G Sutcliffe
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Lancet Infect Dis 8:477-89. 2008....
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sitesPeter D Kwong
Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
Nature 420:678-82. 2002..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
Parallels between cytokinesis and retroviral budding: a role for the ESCRT machineryJez G Carlton
Department of Infectious Diseases, King s College London School of Medicine, London, UK
Science 316:1908-12. 2007..Thus, HIV-1 budding and cytokinesis use a similar subset of cellular components to carry out topologically similar membrane fission events...
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 VpuLiwei Rong
McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
J Virol 83:7536-46. 2009....
High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological statesKevin A Wilkinson
Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina, United States of America
PLoS Biol 6:e96. 2008..High-throughput SHAPE reveals a comprehensive view of HIV-1 RNA genome structure, and further application of this technology will make possible newly informative analysis of any RNA in a cellular transcriptome...
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune controlStephen A Migueles
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Immunity 29:1009-21. 2008..They also demonstrate that lytic granule contents of memory cells are a critical determinant of cytotoxicity that must be induced for maximal per-cell killing capacity...
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infectionNeil M Flynn
University of California at Davis Medical Center, USA
J Infect Dis 191:654-65. 2005..10, adjusted for multiple subgroup comparisons). CONCLUSIONS: There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches...
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposesR S Janssen
Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
JAMA 280:42-8. 1998..Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention...
Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 VpuChristine Goffinet
Department of Infectious Diseases, Virology, University of Heidelberg, Im Neuenheimer Feld 324, D 69120 Heidelberg, Germany
J Virol 84:4089-94. 2010..Thus, Vpu can efficiently antagonize virion tethering in the absence of CD317 degradation...
Inhibiting sexual transmission of HIV-1 infectionRobin J Shattock
Department of Cellular and Molecular Medicine, Infectious Diseases, St George s Hospital Medical School, London, UK
Nat Rev Microbiol 1:25-34. 2003....
Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidenceBharat S Parekh
Division of AIDS, STD, TB Laboratory Research, and Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
AIDS Res Hum Retroviruses 18:295-307. 2002..This assay should be useful for detecting recent HIV-1 infection and for estimating incidence among diverse HIV-1 subtypes worldwide...
A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infectionRajnish Kaushik
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
Cell Host Microbe 6:68-80. 2009..Collectively, our results indicate that the relative ability of lentiviruses and gammaretroviruses to transduce nondividing myeloid cells is dependent upon their ability to neutralize a cellular restriction...
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotypeAsier Saez Cirion
Unité de Régulation des Infections Rétrovirales, Institut Pasteur, 75725 Paris, France
Proc Natl Acad Sci U S A 104:6776-81. 2007..This constitutive antiviral capacity of CD8(+) T cells could account for the control of viral replication in HIC...
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresMargaret Johnson
Royal Free Hospital, London, UK
AIDS 19:685-94. 2005....
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral loadJ A Arranz Caso
Infectious Diseases Unit, Hospital Principe de Asturias, Madrid, Spain
HIV Med 6:353-9. 2005..To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment...
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patientsJade Ghosn
Department of Infectious and Tropical Diseases, , Paris, France
AIDS 19:1643-7. 2005....
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trialEdwin DeJesus
IDC Research Initiative, Altamonte Springs, FL, USA
Clin Infect Dis 39:411-8. 2004..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapyJ C Couto-Fernandez
Laboratorio de AIDS e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz FIOCRUZ, 21045 900 Rio de Janeiro, RJ, Brazil
Mem Inst Oswaldo Cruz 100:73-8. 2005..The maintenance of resistance genotyping programs for HIV-1 failing patients is important to the management of ARV therapies and to attempt and monitor the HIV-1 subtype prevalence in Brazil...
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patientsClotilde Allavena
Service des Maladies Infectieuses et Tropicales/IFR26, , Nantes, France
J Acquir Immune Defic Syndr 39:300-6. 2005..CONCLUSION: The lopinavir/ritonavir-efavirenz combination is associated with a high rate of virologic response and should be compared with more classic NRTI-containing regimens in randomized and controlled clinical trials...
Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progressionJ Vaclavikova
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam 2, 166 10 Prague, Czech Republic
Acta Virol 49:29-36. 2005..Efficient yet temporary suppression of viral replication was achieved by a lopinavir (LPV) treatment...
Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapyL Sarmati
Department of Public Health, University of Rome Tor Vergata, Rome
New Microbiol 27:95-8. 2004..1-74.5%). The HIV strains of patients failing HAART showed a progressive impaired replication capacity. In patients failing HAART the impaired replication capacity of HIV strains could justify the persistence of an immune recovery...
Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in MexicoM Escoto-Delgadillo
Laboratory of Immunodeficiencies and Human Retrovirus, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Mexico
HIV Med 6:403-9. 2005....
Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of BrazilAna Maria Salustiano Cavalcanti
Laboratório Central da Secretaria de Saúde, Secretaria de Saúde do Estado de Pernambuco, Recife, PE, 50050 210, Brazil
Mem Inst Oswaldo Cruz 102:785-92. 2007..The present study showed that there was a high frequency of primary mutations, which offered resistance to nrti and nnrti. Monitoring patients with treatment failure is an important tool for aiding physicians in rescue therapy...
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionRoy M Gulick
Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
AIDS 21:813-23. 2007..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection...
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in childrenH Green
MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
AIDS 21:947-55. 2007..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimenMartin Stürmer
J W Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
Antivir Ther 12:25-30. 2007....
Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infectionPaul Palumbo
Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
J Infect Dis 196:23-9. 2007..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches...
Antiretroviral resistanceAnna Maria Geretti
J HIV Ther 11:72-3. 2006
High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAARTHeungsup Sung
Department of Microbiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
AIDS Res Hum Retroviruses 23:1223-9. 2007..As the first report on resistance mutations to HAART in Korea, our data suggest that genotyping-guided treatment as well as education for compliance are required for better care...
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapiesR Scott Braithwaite
Section of General Internal Medicine, Department of Medicine, Yale University, 950 Campbell Avenue, West Haven, CT 06516, USA
AIDS 21:1579-89. 2007..We aimed to determine adherence, virological, and immunological outcomes one year after starting a first combination antiretroviral therapy (ART) regimen...
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPatrick F Smith
Hoffman La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110 1199, USA
Antimicrob Agents Chemother 51:3574-81. 2007..45 log(10), with individual patients having reductions of greater than 0.7 log(10). No bevirimat resistance mutations were detected during the course of the study...
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimenDiane Descamps
Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
Antivir Ther 11:701-5. 2006..This study examined whether, in the context of a first-line abacavir/lamivudine highly active antiretroviral therapy (HAART) regimen, K65R might occur as a minority population where L74V was detected at virological failure...
Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction proceduresGiovanni Battista La Sala
Division of Obstetrics, Gynecology and Reproduction Medicine, ASMN Reggio Emilia, Italy
AIDS 21:377-9. 2007..001). These findings emphasize the negative role of HAART, but not of HIV-1 infection, in determining semen alterations...
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez
Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
J Med Virol 79:105-10. 2007..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully...
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)S H Lowe
International Antiviral Therapy Evaluation Center IATEC, University of Amsterdam, Amsterdam, The Netherlands
HIV Clin Trials 6:235-45. 2005..To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen...
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected childrenMarkus B Funk
Children s Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
Eur J Med Res 10:503-8. 2005..In an intent-to-treat study, reduction of viral load, increase in CD4 cell count, clinical benefit and adverse reactions were examined in HIV-infected children receiving first line therapy including efavirenz...
Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinicTania Purkayastha
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, AIDS Center Schiff 1, 111 East 210th Street, Bronx, NY 10467, USA
AIDS Patient Care STDS 19:785-93. 2005..Computerized query of the hospital information system proved to be a powerful tool for the identification of study patients in a real-world clinic environment...
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of timeJade Ghosn
Laboratoire de Virologie, CHU Necker Enfants Malades, Université René Descartes Paris, France
AIDS 20:159-70. 2006....
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessDavid R Bangsberg
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, UCSF, San Francisco, California 94143 1372, USA
AIDS 20:223-31. 2006....
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna
Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
AIDS 20:795-803. 2006..We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus...
[Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005]Alejandro Afani S
Seccion de Inmunologia, Departamento de Medicina, Hospital Clinico, Universidad de Chile, Santiago, Chile
Rev Med Chil 135:1237-44. 2007..Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance...
Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysisJavier Ena
HIV Unit, Department of Internal Medicine, Hospital Marina Baixa, Avda Alcalde En Jaime Botella Mayor 7, 03570 Villajoyosa, Alicante, Spain
Enferm Infecc Microbiol Clin 24:232-7. 2006..We incorporated the latest available information to evaluate the net benefit of using resistance testing in HIV-infected patients with virological failure...
Viral replication under combination antiretroviral therapy: a comparison of four different regimensAzra C Ghani
Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK
J Acquir Immune Defic Syndr 30:167-76. 2002..04; 95% CI, 1.0-1.07). Measurement of viral load after approximately 7 days provided the most accurate measure of the degree of viral suppression induced by a given drug regimen...
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overviewJohn A Bartlett
Duke University Medical Center, Durham, North Carolina 27710, USA
HIV Clin Trials 8:221-6. 2007..However, the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) components may also affect efficacy...
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II studyChristine Katlama
Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
AIDS 18:1299-304. 2004..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up studyChristian Laurent
, France
AIDS 16:1363-70. 2002..Contrary to other recent studies in Africa, viral resistance rarely emerged...
The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/mlPhilippa J Easterbrook
Department of HIV/GUM, Guy's, King's and St Thomas' School of Medicine, King's College Hospital, London, UK
AIDS 16:1521-7. 2002..This supports the adoption of a more pro-active approach to treatment intensification and the need for caution with structured treatment interruptions...
Successful simplification of HAART in patients with acute primary HIV infectionA Sinicco
Department of Infectious Diseases, University of Turin, Italy
J Biol Regul Homeost Agents 16:69-72. 2002....
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapyRieneke M E van Praag
National AIDS Therapy Evaluation Center (NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
AIDS 16:719-25. 2002..CONCLUSION: This proof-of-principle study demonstrates that the use of an alternative multidrug regimen results in stronger long-term suppression of pVL compared with clinically successful treatment with standard therapy...
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapySoo Aleman
Division of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, S-141 86 Stockholm, Sweden
AIDS 16:1039-44. 2002..This serial accumulation of mutations is likely to exhaust future drug options..
Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudineRené Anatole Ekpini
Projet RETRO CI, BP 1712, 01 Abidjan, Cote d Ivoire
AIDS 16:625-30. 2002..To describe changes in HIV-1 plasma viral load (VL) and CD4 cell counts and to assess zidovudine resistance associated with a short course of oral zidovudine during late pregnancy...
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapyCalvin J Cohen
Community Research Initiative of New England, Boston, MA 02215, USA
AIDS 16:579-88. 2002..003). CONCLUSION: Antiretroviral treatment guided prospectively by PRT led to the increased use of "active" antiretroviral agents and was associated with a significantly better virological response...
Research Grants
- Tat TransactivationBORIS MATIJA PETERLIN; Fiscal Year: 2010..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
- Tat TransactivationB Matija Peterlin; Fiscal Year: 2007..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
- Establishment fo HIV infection in cotton ratsJorge Blanco; Fiscal Year: 2007....
- TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PXMichael Green; Fiscal Year: 2004..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
- Structure and Function of Ribonucleoprotein Complexes Modulating HIV ReplicationTariq M Rana; Fiscal Year: 2010..These results would also be valuable in developing new strategies for blocking the expression of retroviral or other disease- related genes. ..
- Cytidine deaminase and HIV-1 replicationHui Zhang; Fiscal Year: 2007..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
- Targeting Viral Envelope Glycoproteins with Synthetic AntibodiesJonathan Lai; Fiscal Year: 2010..We are using this new technology to identify novel antibodies against viral targets. This work will provide new tools to understand viral infection and how this process can be inhibited by therapeutic agents or vaccines. ..
- Methamphetamine, HIV, Neuroinflammation and BehaviorRodney Johnson; Fiscal Year: 2007..Therefore, the goal of this proposal is to investigate if MA use and HIV-1 infection unite to exacerbate the cognitive and motor complications associated with HIV disease and produce a heightened neuroinflammatory state. ..
- The Enzymology of M-MuLV and HIV ReplicationJAMES CHAMPOUX; Fiscal Year: 2007..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
- The Enzymology of M-MuLV and HIV ReplicationJAMES CHAMPOUX; Fiscal Year: 2009..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
- High Specificity HIV-1 Markers Predictive of Neuro-AIDSBrian Wigdahl; Fiscal Year: 2010....
- Single and multi-component biguanide-based microbicidesMohamed Labib; Fiscal Year: 2007....
- HIV vectors for stem cell and intrakine gene deliveryRichard Sutton; Fiscal Year: 2004..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
- MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYSKarin Musier Forsyth; Fiscal Year: 2001..c) Stopped-flow fluorescence techniques will be used to investigate the kinetic mechanism of NC unwinding and annealing of tRNALys,3. ..
- 3D Structure of HIV-1 psi-SiteDaniele Fabris; Fiscal Year: 2005..abstract_text> ..
- MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESISCindy Morris; Fiscal Year: 2002....
- HIV-1 chemoprophylaxis and archived drug resistance in infantsDeborah Persaud; Fiscal Year: 2007....
